These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12113871)

  • 21. Urinary tract infection: traditional pharmacologic therapies.
    Nicolle LE
    Dis Mon; 2003 Feb; 49(2):111-28. PubMed ID: 12601341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.
    Gupta K; Hooton TM; Stamm WE
    Ann Intern Med; 2001 Jul; 135(1):41-50. PubMed ID: 11434731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Urinary tract infections: risk factors and therapeutic trends].
    Margariti PA; Astorri AL; Mastromarino C
    Recenti Prog Med; 1997 Feb; 88(2):65-8. PubMed ID: 9148368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection.
    Hooton TM
    Int J Antimicrob Agents; 2003 Oct; 22 Suppl 2():65-72. PubMed ID: 14527774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.
    Henry DC; Bettis RB; Riffer E; Haverstock DC; Kowalsky SF; Manning K; Hamed KA; Church DA
    Clin Ther; 2002 Dec; 24(12):2088-104. PubMed ID: 12581547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial resistance in uncomplicated urinary tract infections in 3 California EDs.
    Moffett SE; Frazee BW; Stein JC; Navab B; Maselli J; Takhar SS; Gonzales R
    Am J Emerg Med; 2012 Jul; 30(6):942-9. PubMed ID: 21802879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.
    Walbrown MA; Aspinall SL; Bayliss NK; Stone RA; Cunningham F; Squier CL; Good CB
    J Manag Care Pharm; 2008; 14(1):34-40. PubMed ID: 18240880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The current management strategies for community-acquired urinary tract infection.
    Hooton TM
    Infect Dis Clin North Am; 2003 Jun; 17(2):303-32. PubMed ID: 12848472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and risk factors for trimethoprim-sulfamethoxazole-resistant Escherichia coli among women with acute uncomplicated urinary tract infection in a developing country.
    Gangcuangco LM; Alejandria M; Henson KE; Alfaraz L; Ata RM; Lopez M; Saniel M
    Int J Infect Dis; 2015 May; 34():55-60. PubMed ID: 25748571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates.
    Johnson L; Sabel A; Burman WJ; Everhart RM; Rome M; MacKenzie TD; Rozwadowski J; Mehler PS; Price CS
    Am J Med; 2008 Oct; 121(10):876-84. PubMed ID: 18823859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance.
    Miller LG; Tang AW
    Mayo Clin Proc; 2004 Aug; 79(8):1048-53; quiz 1053-4. PubMed ID: 15301333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of quinolone versus trimethoprim-sulfamethoxazole use for outpatient urinary tract infection.
    Stuck AK; Täuber MG; Schabel M; Lehmann T; Suter H; Mühlemann K
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1359-63. PubMed ID: 22232276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Allergy and Resistance on Antibiotic Selection for Recurrent Urinary Tract Infections in Older Women.
    Malik RD; Wu YR; Christie AL; Alhalabi F; Zimmern PE
    Urology; 2018 Mar; 113():26-33. PubMed ID: 29196069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.
    Onrust SV; Lamb HM; Balfour JA
    Drugs; 1998 Nov; 56(5):895-928. PubMed ID: 9829160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing antibiotic resistance.
    Gupta K
    Am J Med; 2002 Jul; 113 Suppl 1A():29S-34S. PubMed ID: 12113869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group.
    McCarty JM; Richard G; Huck W; Tucker RM; Tosiello RL; Shan M; Heyd A; Echols RM
    Am J Med; 1999 Mar; 106(3):292-9. PubMed ID: 10190377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which fluoroquinolones are suitable for the treatment of urinary tract infections?
    Naber KG
    Int J Antimicrob Agents; 2001 Apr; 17(4):331-41. PubMed ID: 11295418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxazole.
    Guibert J; Capron MH
    J Int Med Res; 1992 Nov; 20(6):467-74. PubMed ID: 1337525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.